Mark Grose

The HOPE (Heart Outcomes Prevention Evaluation) Study: The design of a large, simple randomized trial of an angiotensin converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events

F Mindlen, Roberto Nordaby, M I Soto Ruiz et al. · Queensland's institutional digital repository (The University of Queensland) · 1996 · 154 citations

Medicine, Cardiology, Pharmacotherapy +17

Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder Cancer

Nicola Annels, David Mansfield, Mehreen Arif et al. · Clinical Cancer Research · 2019 · 123 citations · Full text

Life Sciences, Immunology, Pharmacology +5

Effects of Cyclosporine on Glucose Tolerance in the Rat

J.‐F. Yale, R D Roy, Mark Grose et al. · Diabetes · 1985 · 71 citations · Full text

Medicine, Endocrinology, Pharmacology +11

Final data from CALM: A phase II study of Coxsackievirus A21 (CVA21) oncolytic virus immunotherapy in patients with advanced melanoma.

Robert Hans Ingemar Andtbacka, Brendan D. Curti, Howard L. Kaufman et al. · Journal of Clinical Oncology · 2015 · 67 citations

Medicine, Immunology, Oncology +17

A phase 1b single-arm trial of intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma: results from the CAPRA study

Ann W. Silk, Steven O’Day, Howard L. Kaufman et al. · Cancer Immunology Immunotherapy · 2022 · 46 citations · Full text

Medicine, Immunology, Oncology +17